Predicting Pharmacokinetics in Rats Using Machine Learning: A Comparative Study Between Empirical, Compartmental, and PBPK-Based Approaches.

Journal: Clinical and translational science
PMID:

Abstract

A successful drug needs to combine several properties including high potency and good pharmacokinetic (PK) properties to sustain efficacious plasma concentration over time. To estimate required doses for preclinical animal efficacy models or for the clinics, in vivo PK studies need to be conducted. Although the prediction of ADME properties of compounds using machine learning (ML) models based on chemical structures is well established in drug discovery, the prediction of complete plasma concentration-time profiles has only recently gained attention. In this study, we systematically compare various approaches that integrate ML models with empiric or mechanistic PK models to predict PK profiles in rats after intravenous administration prior to synthesis. More specifically, we compare a standard noncompartmental analysis (NCA)-based approach (prediction of CL and V), a pure ML approach (non-mechanistic PK description), a compartmental modeling approach, and a physiologically based pharmacokinetic (PBPK) approach. Our study based on internal preclinical data shows that the latter three approaches yield PK profile predictions of comparable accuracy across a large data set (evaluated as geometric mean fold errors for each profile of over 1000 small molecules). In summary, we demonstrate the improved ability to prioritize drug candidates with desirable PK properties prior to synthesis with ML predictions.

Authors

  • Moritz Walter
    Department of Chemistry, Centre for Molecular Informatics, University of Cambridge, Lensfield Road, Cambridge, CB2 1EW, UK.
  • Ghaith Aljayyoussi
    Boehringer Ingelheim Pharma GmbH & Co. KG, Drug Discovery Sciences, Preclinical PKPD Modelling and Data & Digital Sciences, Biberach, Germany.
  • Bettina Gerner
    Boehringer Ingelheim Pharma GmbH & Co. KG, Drug Discovery Sciences, Preclinical PKPD Modelling and Data & Digital Sciences, Biberach, Germany.
  • Hermann Rapp
    Boehringer Ingelheim Pharma GmbH & Co. KG, Drug Discovery Sciences, Preclinical PKPD Modelling and Data & Digital Sciences, Biberach, Germany.
  • Christofer S Tautermann
    Boehringer Ingelheim Pharma GmbH & Co. KG, Medicinal Chemistry, Computational Chemistry, Biberach, Germany.
  • Pavel Balazki
    ESQlabs GmbH, Saterland, Germany.
  • Miha Škalič
    Computational Biophysics Laboratory, Universitat Pompeu Fabra , Parc de Recerca Biomèdica de Barcelona, Carrer del Dr. Aiguader 88, Barcelona 08003, Spain.
  • Jens M Borghardt
    Drug Discovery Sciences Department, Boehringer Ingelheim Pharma GmbH & Co. KG, Birkendorfer Str. 65, 88397, Biberach an der Riss, Germany.
  • Lina Humbeck
    Medicinal Chemistry Department, Boehringer Ingelheim Pharma GmbH & Co. KG, Birkendorfer Str. 65, 88397 Biberach an der Riss, Germany.